[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported equity-related transactions in company common stock.
Rhea-AI Filing Summary
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported equity-related transactions in company common stock. On February 3, 2026, he acquired 44,867 shares of common stock at $0 per share, tied to performance share awards granted on March 10, 2023 and March 10, 2024.
These awards vested after the Compensation and Talent Committee certified achievement of performance goals, though shares from the March 10, 2024 grant will only be issued once additional service requirements are met. On the same date, he had a disposition coded "F" of 24,802 shares at $143.28 per share. Following these transactions, Dickinson directly owns 170,568 shares of Gilead common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 44,867 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 24,802 | $143.28 | $3.55M |
Footnotes (1)
- F1. Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2023 and March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares certified for grants made March 10, 2024 will not be issued to the Reporting Person until the requisite continuing service requirements are also met.
AI-generated analysis. How Rhea-AI works. Not financial advice.